New RNA-based therapy combats melanoma in mouse models

New York, NY (July 27, 2023)—Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

The findings, which suggest that the approach has the potential to be effective against tumors that have already spread to other parts of the body and against different cancer types, were reported in the July 27 issue of Nature Nanotechnology [DOI: 10.1038/s41565-023-01453-9].

Cancer cells employ strategies to switch off various stages of the cancer-immunity cycle, the process by which dendritic cells educate T cells to kill cancer cells. This immunosuppressive environment that impedes activation of cancer-killing T cells allows tumors to grow, say the researchers.

“Most approaches to boost this critical role of dendritic cells—or adoptive cell therapies—aim to increase the activation signals provided to dendritic cells when specific molecules on their surface bind to tumor cells. However, these have not been as successful in clinical trials as hoped. This is because tumors have a tendency to evolve in different ways to switch off each stage of the cancer-immunity cycle,” says Yizhou Dong, PhD, corresponding author of the study, Professor of Oncological Sciences, and a member of the Icahn Genomics Institute and the Marc and Jennifer Lipschultz Precision Immunology Institute at Icahn Mount Sinai.

The researchers named their approach CATCH. As part of the regimen, the researchers used new types of lipid nanoparticles to deliver two mRNA therapeutics—a process similar to that used successfully for COVID-19 vaccines—to ensure the dendritic cells were sufficiently activated to enhance the cancer-immunity cycle in established tumors.

Using multiple bioassays to gain insights on the effects of the CATCH regimen on different types of immune cells, the researchers showed that their strategy not only reactivated the cycle but also removed obstacles at other stages. This caused a change in the tumor’s microenvironment, shifting it from having cell types that weaken T cells’ ability to fight cancer to having cell types that actually support and enhance their ability to fight tumors.

Beyond the positive findings in mouse models of melanoma, the researchers conducted further tests to evaluate the effectiveness of the CATCH regimen in restarting the cancer immunity cycle more broadly. Their investigations revealed encouraging results, as the regimen reduced tumors in mouse models of B cell lymphoma by 83 percent. They also tested it in mouse models of breast cancer, where approximately half of the mice favorably responded.

Next, the researchers plan feasibility and safety testing for using the CATCH regimen in early-phase clinical trials for patients.

“Dendritic cells have been a key focus for the development of new cancer therapies as these cells organize the cancer-immunity cycle. In theory, the CATCH regimen using this particular RNA-based technology has the potential to provide a much more effective approach for using dendritic cells for cancer immunotherapy to treat a wide range of solid tumors,” says Brian Brown, PhD, Director of the Icahn Genomics Institute and Associate Director of the Marc and Jennifer Lipschultz Precision Immunology Institute at Icahn Mount Sinai.

The paper is titled “Close the Cancer-Immunity Cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy.”

The remaining authors are Yuebao Zhang (Ohio State University), Xucheng Hou (Ohio State University, Icahn Mount Sinai), Shi Du (Ohio State University, Icahn Mount Sinai), Yonger Xue (Ohio State University, Icahn Mount Sinai), Jingyue Yan (Ohio State University, Icahn Mount Sinai), Diana D. Kang(Ohio State University, Icahn Mount Sinai), Yichen Zhong (Ohio State University, Icahn Mount Sinai), Chang Wang (Ohio State University, Icahn Mount Sinai), Binbin Deng (Ohio State University), and David W. McComb (Ohio State University).

The study was funded in part by National Cancer Institute grant P30 CA016058 and National Institute of General Medical Sciences grant R35GM144117.

To view competing interests, please see the paper at Nature Nanotechnology.  

-####-

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.  

Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases. 

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System. 

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.